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Abstract
Objective
Illness Management and Recovery (IMR) is a psychosocial intervention with a recovery-ori-
ented approach. The program has been evaluated in different settings; however evidence
for the effects of IMR is still deficient. The aim of this trial was to investigate the benefits and
harms of the IMR program compared with treatment as usual in Danish patients with schizo-
phrenia or bipolar disorder.
Method
The trial was designed as a randomized, assessor-blinded, multi-center, clinical trial investi-
gating the IMR program compared with usual treatment. 198 people diagnosed with schizo-
phrenia or bipolar disorder participated. The primary outcome was the Global Assessment
of Functioning (GAF-F) at the end of intervention and the secondary and explorative out-
comes included severity of symptoms and service utilization.
Results
IMR had no significant effect on functioning, symptoms, substance use or service utilization.
Conclusion
This randomized trial contributes to the evidence base of IMR by providing a methodological
solid base for its conclusions; however the trial has some important limitations. More
research is needed to get a firm answer on the effectiveness of the IMR.
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Introduction
Illness Management and Recovery (IMR) is a curriculum-based rehabilitation program devel-
oped to help people with severe mental illness improve their illness self-management and to
obtain a decreasing severity of symptoms, increase level of functioning, and achieve prolonged
remission [1]. Previously, five randomized trials, investigating IMR have been conducted with
varying sizes and design, among others four randomized on an individual level [2–5], whereas
one used a cluster randomization design [6].
The findings from four of these trials indicate that IMR is effective in terms of clinical
recovery measures. Participants receiving IMR showed significant improvements in psychiat-
ric symptoms, that is positive symptoms, negative symptoms, symptoms of depression [2,4], in
coping with symptoms [3], in psychosocial functioning [4], reduced hospital use over time [5],
and less suicidal ideation [2] compared with participants who receive treatment as usual. The
latest published trial investigating IMR versus an active control group reported that IMR was
not significantly different from the control group on symptoms, medication adherence, or ser-
vice utilization, but there were very low rates of retention in both the IMR and control groups
over the study period [6]. The results from these trials should, however, be interpreted with
caution. All trials lack one or more desirable aspects of controlled clinical trials, such as power
and sample size calculation, outcome assessment by blinded assessors, or systematic approach
to handling missing data, resulting in an increased risk of bias. Consequently, the intention
with this trial was to add knowledge to the existing evidence of the IMR program by meeting
the highest standards of methods in a randomized clinical trial.
The aim of this randomized trial was to investigate the effects of the IMR program com-
pared with treatment as usual in Danish patients with schizophrenia or bipolar disorder. The
following hypothesis was tested: Participants in the IMR program would score higher than par-
ticipants receiving treatment as usual on the Global Assessment of Function scale (GAF-F) at
the end of the 9 month intervention period. In this paper, the results on the clinical outcomes:
functioning, symptom severity, social functioning, drug/alcohol abuse, and service utilization
will be presented. Results regarding self-perceived recovery have been presented elsewhere [7].
Methods
Design
The trial was designed as a randomized, assessor-blinded, multi-center, clinical trial of the
IMR program compared with treatment as usual in community mental health centers in the
Capital Region of Denmark with a post-intervention assessment and a one-year follow-up; see
the trial protocol [8].
Recruitment
Participants were recruited from three community mental health centers (CMHC) in the Capi-
tal Region of Denmark. To increase the number of participants enrolled in the study an addi-
tional community mental health center was added to the original two. The project was
planned in collaboration with the heads of management at the first two of the three CMHC, all
of which had shown commitment to implement IMR.
Participants
Eligible participants were at least 18 years old, receiving services from one of the CMHCs,
diagnosed according to the ICD-10 criteria with schizophrenia or bipolar disorder, able to
speak and understand Danish, and provided written informed consent. The Present State
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Examination [9] was used to verify the diagnosis prior entering the trial. Patients were
excluded if they had a guardian or a forensic arrangement, or met the criteria for ICD-10 diag-
nosis of dementia or mental retardation, had an active substance use disorder, lived in a com-
munity residential home as treatment as usual is different for this group, or were involved in
psychoeducation at the time of inclusion.
Randomization
After the baseline assessment, participants were randomly allocated to IMR plus treatment as
usual or treatment as usual alone. To secure the concealment of the allocation sequence, the
randomization was central and telephone-based through an administrative office unrelated to
the research team. The allocation sequence was stratified by diagnosis and CMHC. The alloca-
tion sequence was computer-generated using permuted blocks varying in sizes of 6, 8 and 10.
Randomization was done one at a time and on average the patients in the intervention group
waited 87 days (SD 77) before the first group session was held and 62% of the patients waiting
under 90 days before the first group session took place.
Interventions
The illness management and recovery program. Patients randomized to the experimen-
tal intervention were offered group-based IMR plus treatment as usual (see below). IMR is a
curriculum-based program organized in 11 modules which consist of: recovery strategies;
practical facts about mental illness; the stress-vulnerability model; building social support;
using medication effectively; drug and alcohol use; reducing relapses; healthy lifestyle; coping
with stress; coping with problems and symptoms; and getting your needs met in the mental
health system. IMR was provided in a group format with weekly one-hour sessions over a
period of nine months. Ten patients were assigned to each group which was facilitated by two
or three practitioners. IMR was conducted using a closed enrollment group format, such that
once the group was started new participants were not enrolled into it (IMR has also been con-
ducted using open group formats). Strategies such as motivational phone calls and in-hospital-
sessions were employed to motivate participants to attend and to be engaged in the IMR pro-
gram. A further description of the IMR program can be found elsewhere [8, 10].
Treatment as usual. Participants randomized to the control group received treatment as
usual only, which included individually adapted interdisciplinary treatment at the CMHC or
in the patient’s own home. Treatment included medication, case management, group therapy
(i.e. cognitive behavioral therapy), as well as unstandardized psycho-education. Staff members
across the three CMHCs had comparable levels of education and years of experience working
with people with severe mental illness. Every patient had a case manager who together with the
patient planned the individualized treatment. The patient met with case manager at the
CMHC or at home or attended other activities at the community mental health center approxi-
mately once a week.
Outcomes
Baseline assessments were conducted from February 2011 till December 2012 and follow-up
assessments from March 2012 till December 2013. The primary outcome was global function-
ing post-intervention assessed by the Global Assessment of Functioning (GAF-F). The GAF
scale can be divided into two scales GAF-F and GAF-S (one that focuses on functioning and
one that focuses on symptoms) [11–13]. In this trial the focus of the primary outcome was
functioning which is why the GAF-F scale was used. The secondary outcomes were symptom
severity on Positive and Negative Syndrome Scale (PANSS) [14] and social functioning on
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Personal and Social Performance Scale (PSP) [15]. The PANSS has been validated in Danish
[14] but not the PSP scale. Exploratory outcomes were symptoms on the GAF-S, depression
on the Hamilton Rating Scale for Depression (HAM-6) [16, 17], mania on Young Mania Rat-
ing Scale (YMRS) [18], substance abuse (assessed by the case manager), and service utilization
based on hospital records.
Assessment of implementation
The IMR Fidelity Scale [10] was used to assess fidelity to the IMR in all the groups. A multiple
data approach was used including interviews, observation of the IMR group, an audit of the
patient service records as well as audits of the IMR notes of progress. The fidelity assessments
were made half-way through the program (after 4 months) and at the end of the intervention
for each IMR group (9 months).
Power and sample size
Prior to recruitment a sample size of 200 participants was estimated sufficient for detecting a
true difference in the IMR and control group of at least 6 points on the GAF-F. The few previ-
ous studies using IMR or elements of IMR, where the effectiveness has been assessed by using
the total GAF score, have showed a difference from 6 to 10 points [19, 20]. Based on this
knowledge we conservatively estimated the true difference in the experimental and control
group means to be 6 points on the GAF-F score. The sample size calculation was furthermore
based on a power of 80%, an alpha of 5% and a standard deviation (SD) of 15 points [21, 22].
For the secondary outcomes it was determined that the sample size of 200 participants was suf-
ficient to test minimal clinically relevant differences with an alpha of 5% and a power of 80%.
See the trial protocol for more information on power and sample size calculation [8].
Blinding
Post intervention assessments were conducted by assessors who were blind to treatment allo-
cation. Two different assessors performed the assessments, and therefore the assessors rated
together to reach agreement before rating patients individually to ensure inter-rater reliability.
Analysis of these data showed an acceptable inter-rater reliability (S1 Text). Participants as
well as the staff were strongly inculcated not to disclose the allocation status of the participant
at the follow up assessment. The statistical analyses were conducted with the two intervention
groups coded as A and B, and the Steering Committee drew the conclusions with the blind still
intact. In order to secure this blinding the analyses exploring the interactions between degree
of participation in IMR and outcomes were carried out after all the other analyses were
completed.
Statistical analysis
The data analysis was based on the intention-to-treat principle. The analysis of difference
between the two groups was conducted using analysis of covariance for the continuous pri-
mary and secondary outcome measures (GAF-F, GAF-S, PSP, and PANSS). This was esti-
mated as marginal means adjusted for the baseline value of the variable in question [23].
Independent sample t-tests were conducted for the variables concerning substance use, service
utilization, that is number and length of hospital admission and number of emergency service
visits together with number of visit to the community mental health center (use of treatment
as usual) and harm and adverse effect. As service utilization and harms and adverse effects
were measured during the study period no baseline mean existed. As missing data is a potential
Illness management and recovery: Clinical outcomes of a randomized trial
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source of bias a strategy of conducting an analysis using multiple imputations were decided
beforehand [8]. An analysis of missing data was conducted for the primary and secondary vari-
ables GAF-F, PSP, and PANSS and it showed that up to 23% of all observations were incom-
plete. Therefore, multiple imputation with chained equations under the assumption of data
missing at random (MAR) was conducted to enable intention-to-treat analyses. Post-treat-
ment values were imputed for GAF-F, PSP, and PANSS, using baseline values of all three vari-
ables, sex, diagnosis, age, community mental health center and intervention group as
covariates. The automatic procedure was used and 100 imputations estimated. Per-protocol
analysis was performed to see if group attendance influenced the result as proposed in one trial
[24]. An analysis using the continuous variable of group attendance for the participants ran-
domized to IMR was made as well as an analysis using a dichotomous variable categorizing
attendance into 0–10 sessions or11 sessions. Subgroup analyses tested whether diagnosis or
sex interacted with the primary and secondary outcomes. The level of significance for all statis-
tical tests was 0.05. The IBM SPSS Statistics version 19 for Windows was used for statistical
analysis and STATA /SE version 13.1 was used for multiple imputations.
Ethical considerations and information to participants
Patients were recruited from the involved community mental health centers in the Capital
Region of Denmark by their case manager supported by a local IMR supervisor. The patients
were informed about the on-going trial by a poster in the waiting room and verbally by their
case manager. If they were interested in participating they received more information about
the IMR program and what their role would be in the controlled trial both verbally and writ-
ten. Interested participants provided consent verbally and in writing. The case managers were
informed about the trial and how to provide information to the patients by the researchers, the
local IMR supervisor and their management. The trial was approved by the Ethics Committee
in the Capital Region of Denmark (H-1-2010-134) January 20th 2011, before recruiting
patients, reported to the Danish Data Protection Agency (RHP-2011-09) during 2011, and reg-
istered on www.clinicaltrials.gov (NCT01361698). The authors confirm that all ongoing and
related trials for this intervention are registered.
Results
Fig 1 shows the CONSORT diagram for the participants through the trial. 202 participants
were included and randomized but four of them were excluded immediately after randomiza-
tion: Two participants from the control group withdrew their informed consent, one partici-
pant from the control group did not meet the criteria for diagnosis after all, and one
participant was assigned as the only participant in an IMR group, that was never conducted
and therefore the research group decided to exclude this individual from the trial instead.
Therefore, 198 participants entered the trial, 99 participants in each intervention group.
The baseline characteristics of the 198 participants are listed in Table 1, showing an equally
distributed in the two groups. A total of 26 participants from the IMR group and 11 from the
control group did not participate in the follow-up assessments, a statistically significant differ-
ence (χ2 = 7.48, df = 1, p = 0.006). The reason for drop-out was that most patients in both
groups simply did not want to continue participating with a higher percentage giving this
answer in the intervention group compared to the control group (55% vs. 45%).
Exposure to IMR in the intervention group
The exposure to IMR in the intervention group is shown in Table 2. The exposure rate was
57.6%, as 57 of the 99 participants attended 10 or more IMR sessions. Among all the
Illness management and recovery: Clinical outcomes of a randomized trial
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participants mean number of sessions were 16.4 (SD 13.3), compared to a mean of 26.1 (SD
8.1) among the 58, who participated in 10+ sessions. To explore if there were any differences
between the non-exposed participants (attending 0–10 sessions) and the exposed participants
(attending 10+ sessions) we did some post-hoc analyses to see, if there was a different in the
time they had to wait from completion of baseline assessment to beginning the first IMR
group as well as differences in baseline characteristics. There were no significant different in
the mean waiting-time for the two groups (S1 Table). Furthermore, there were no significant
differences in sex, age, housing, employment status, education, living status, diagnoses and
substance abuse, but a significant difference in numbers in the two groups when we compared
the three CMHCs (S2 Table).
Fig 1. Flow diagram for the Danish illness management and recovery trial.
https://doi.org/10.1371/journal.pone.0194027.g001
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Table 1. Baseline characteristics of the participants.
IMR (N = 99) TAU† (N = 99)
Variable N % N %
Site
CMHC‡ Ballerup 29 29.3 25 25.3
CMHC Gladsaxe 30 30.3 33 33.3
CMHC Frederiksberg 40 40.4 41 41.4
Sex
Female 45 45.5 44 44.4
Age
Age (mean ±SD) 41 (±11.0) 45 (±11.5)
Age range 20–68 22–77
Housing
Rented housing 75 75.8 65 65.7
Cooperative dwelling 14 14.1 18 18.2
Owner-occupied housing 8 8.1 10 10.1
Homeless 0 0 0 0
Missing data 2 2 6 6.1
Employment status
Employed 7 7.1 12 12.1
Student 5 5.1 0 0
Unemployed or retired 84 84.8 81 81.8
Missing 3 3 6 6.1
Education
Public School 26 26.3 26 26.3
High school 17 17.2 17 17.2
Vocational training 18 18.2 18 18.2
University 27 27.3 29 29.3
Missing 11 11.1 9 9.1
Living status
Alone 70 70.7 69 69.7
Living with spouse and/or children 19 19.2 26 26.3
Other e.g. co-housing scheme 6 6.1 0 0
Missing 4 4 4 4
Diagnosis
Schizophrenia 76 76.8 75 75.8
Bipolar disorder 23 23.2 24 24.2
Recent suicide attempt(s) 2 2 4 4
Alcohol or drug abuse
Alcohol or drug abuse 15 15,2 13 13,1
No abuse 80 80,8 80 80,8
Missing 4 4 5 5.1
Years since first contact (± SD) 14 (±10.3) 16 (±10.2)
Missing 17 17,2 14 14.1
 Illness Management and Recovery
† Treatment as usual
‡ Community Mental Health Center
https://doi.org/10.1371/journal.pone.0194027.t001
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Intention-to-treat analyses
Multiple imputations were used to analyze data according to intention-to-treat principle
(Table 3). IMR was not significantly different from treatment as usual regarding level of func-
tioning assessed by GAF-F, mean difference: +2.5 points (95% confidence interval (CI): -1.4
points to +6.4points, t = 1.25, df = 1, p = 0.21). For the secondary outcomes, there were no
group differences regarding PSP, mean difference: +3.7points (95% CI: -0.8points to +-
8.1points, t = 1.62, df = 1, p = 0.11), or PANSS, mean difference: -2.7points (95% CI: -8.3points
to2.8 points, t = —0.4498, df = 1, p = 0.33).
Complete case analyses
When analyzing data as complete cases, which are all cases where we had observed data on,
similar results were found for GAF-F, PSP, and PANSS as in the intention-to-treat analyses,
please see Table 2. No differences between the two intervention groups were seen in any of the
explorative assessments of GAF-S, HAM-D, and Young Mania Rating Scale.
Service utilization
Treatment as usual that is the number of visits to CMHC (treatment i.e. meetings with the case
manager, meetings with a psychologist or a psychiatrist, or times participating in group activi-
ties) was the same for both groups, see Table 3. IMR participants had a mean of 24.1 visits
(SD = 23.8) and control group participants had a mean of 24.5 visits (SD = 20.2), respectively.
This number covered a wide range where some participants in both groups had no visits and
some had more than 130 visits during the follow-up period. Exposure to IMR in the interven-
tion group is shown in Table 2.
Participants in the IMR group had a mean number of days in the psychiatric hospital of
13.5 (SD = 71.1) whereas participants in the control group had a mean number of 12.5 days
(SD = 46.3), there was no statistically significant difference. There were no significant differ-
ences in the number of times the psychiatric emergency service was used or in number of hos-
pital admissions between the two groups.
Per-protocol subgroup analysis
The results of the three per-protocol subgroup analyses are listed in Table 4. There was no
association between a higher number of sessions attended and the end of intervention GAF-F
score (F = 5.7, df = 1, p = 0.49). Subgroup analyses showed no differences in the effect of IMR
according to diagnosis or sex regarding the outcomes of GAF-F, PSP or PANSS.
Harms and adverse events
In Table 3 is an overview of harms and adverse effects. There were no significant differences
between the two groups in suicide or deaths. Participants in IMR did not differ from
Table 2. Exposure to IMR in the intervention group.
Degree of penetration to IMR among the intervention group (N = 99) n (%)
Participants attending 0 IMR sessions (not engaged) 13 (13.1)
Participants attending only 1 IMR session (minimally engaged) 8 (8.1)
Participants attending 2–9 IMR sessions (engaged but not exposed) 21 (21.2)
Participants attending 10–20 sessions 11 (11.1)
Participants attending more than 20 sessions 46 (46.5)
https://doi.org/10.1371/journal.pone.0194027.t002
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Table 3. Analyses of primary, secondary and explorative outcomes, service utilization, harms and adverse events.
Intention-to- treat-analyses
IMR TAU† P-value‡
Baseline Post-intervention N Baseline Post-intervention N
Mean SD§ Mean SD Mean SD Mean SD
Primary outcome
GAF (F) || 40.4 9.3 46.4 14.6 99 40.7 8.3 44.0 13.3 99 0.21
Secondary outcome
PSP¶ 50.0 11.7 53.3 16.9 99 48.9 11.3 49.6 15.7 99 0.11
PANSS 63.6 15.0 56.6 20.5 99 64.9 14.3 59.4 19.3 99 0.33
Complete cases analysis
IMR TAU P-value
Baseline Post-intervention N Baseline Post-intervention N
Mean SD Mean SD Mean SD Mean SD
Primary outcome
GAF (F) 39.9 7.1 45.9 12.3 72 41.0 7.6 44.3 12.8 81 0.21
Secondary outcome
PSP 49.2 11.4 53.0 13.2 71 49.0 10.5 49.5 14.7 79 0.09
PANSS 64.3 15.5 57.1 16.0 69 64.5 13.4 58.3 17.3 76 0.63
Explorative outcome
GAF-S†† 43.0 9.0 48.2 13.6 63 42.8 9.1 48.2 13.4 75 0.96
HAM-6§§ 6.9 4.0 5.6 4.5 69 6.3 3.6 5.7 3.9 77 0.50
YMRS|||| 8.1 5.1 6.9 5.8 69 7.8 5.1 7.2 5.6 76 0.63
N % n % N % n %
Substance use 12 18 9 13 67 10 14 10 14 74 0.28
Service utilization during the study period
IMR TAU
Mean SD N Mean SD N
Number of hospital admissions 0.6 1.1 99 0.6 1.7 99 0.92
Length of hospital admissions 13.5 37.1 99 12.5 46.3 99 0.87
Use of emergencies services 1.1 2.6 99 1.0 2.6 99 0.83
Use of treatment as usual 24.1 23.8 93 24.5 20.2 94 0.88
Harms and adverse events during the study period
IMR TAU
n % N n % N
Participants attempting suicide 1 1 99 0 0 99 0.28
Participants dying of suicide 0 0 99 1 1 99 0.32
Death (all causes) 1 1 99 2 2 99 0.56
Analyses based on ANCOVA and T-test.
Illness management and recovery
† Treatment as usual
‡ Comparison of means/numbers IMR and TAU group post-intervention
§ Standard deviation
|| Global Assessment of Functioning- Function subscale
¶ Personal and Social Performance
 Positive and Negative Syndrome Scale
†† Global Assessment of Functioning–Symptom subscale
§§ Hamilton Rating Scale for Depression, 6 items
|||| Young Mania Rating Scale
https://doi.org/10.1371/journal.pone.0194027.t003
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participants in the control group in terms of misuse of alcohol or drugs (F = 1.46, df = 1,
p = 0.57). Three participants died in the period of follow-up, one of suicide from the control
group and two died of natural causes, one from each group. No relation between participating
in the IMR trial and the deaths was detected. No further harms or life-threatening conditions
were reported during the trial.
Implementation
Staff specially trained in IMR fidelity assessment from one participating community mental
health center was conducting the assessments at the other community mental health centers’
groups and vice versa. The IMR Fidelity mean score across the three participating community
mental health centers assessed half-way at 4 months was 4.2 (SD 0.3) indicating good fidelity
and the mean score for the end assessment was 4.9 (0.2) indicating high fidelity. A total of 10
IMR groups started and 9 of them completed. One group ended before time because the par-
ticipants could not come to sessions because of personal reasons (e.g., serious hospitalization,
got a job in the day hours, recently had a baby).
Discussion
This trial investigated the benefits and harms of the IMR program compared with treatment as
usual. The trial was designed as an “add-on” study, and therefore patients in the intervention
group received IMR as well as “treatment as usual”. Thereby potential difference between the
two groups can only be explained by the effect of the IMR program. We found no effect on
functioning, symptoms, substance abuse or service utilization. Two of the five earlier studies
on IMR also examined the effect of IMR on functioning. One found no effect [5], but the other
had a positive result [4]. Furthermore two of the five studies examined the effect on symptoms.
Levitt et al. had a conflicting result, as they found a significant effect on a clinicians measured
scale, mainly because of a reduction of the level of depression and anxiety, but no effect on a
self-report scale [4], whereas Fa¨rdig had a positive result [2]. Two studies of the five studies
measured IMR effect on substance abuse, and our result is consistent with these earlier results,
as they found no effect [4, 6]. Finally, four of the five studies measured the effect on service uti-
lization, three with a result in line with ours, as they found no effect [2, 4, 5], but the last study
had a positive result [6]. As the results of all five earlier trials have to be addressed with caution
due to a high risk of bias, one might conclude in line with our study that IMR have no effect
on functioning, symptoms, substance abuse or service utilization. However the present study
also has some limitation, i.e. not as high an exposure to IMR as wanted. Therefore, in order to
get a robust answer to whether IMR is an effective program or not, more research is needed,
among others there is a need for collecting the evidence from randomized trials of IMR in a
systematic review with a meta-analysis, which is under preparation [25].
Strengths and limitations
This trial has several strengths. The trial was conducted with adequate generation of allocation
sequence; adequate allocation concealment; adequate blinding wherever possible; adequate
reporting of all relevant outcomes; intention-to-treat analyses; and no for-profit bias [26–28].
The Illness Management and Recovery Fidelity Score indicated that the implementation of the
program was satisfactory. A strength of this trial is that prior beginning recruitment a sample
size calculation was made. Furthermore, only patients with a validated diagnosis of schizophre-
nia or bipolar disorder were included in the trial. In the randomization process an external
partner conducted the randomization and assured the concealment of sequence and alloca-
tion. It is also strength of the trial that most outcome assessments were conducted blinded, so
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that the knowledge of group status did not influenced the process. The external validity is high
because the included participants represent the majority of patients with severe mental ill-
nesses getting treatment in a community.
However, this trial also has some limitations. It is a limitation that 23 percent of the observed
data were incomplete because the attrition rate was high. The attrition from research was higher in
the IMR group. Our results indicate that the difference in attrition rate mainly is because more par-
ticipants in the intervention group simply just did not want to participate in the follow-up inter-
view. As 50% of the participants who withdraw from the research in the intervention group had
attended zero or only one IMR-group session, one can argue that the main reason for the higher
attrition rate in the intervention group is that these patients were not motivated to participate in
the study all together not the IMR-intervention or the research interview. To address attrition
from research, intention-to-treat analyses were done with multiple imputation. This is the least
biased way to deal with missing data [29]. We may also have been too optimistic when planning
the present trial as we based the number of participants needed to include on a 6 points difference
on the GAF-F scale. Due to this our sample size may be too small, whereby we do not have the
power to state if the observed difference of 2.4 is in fact a true difference, but it is most likely not of
‘clinical’ relevance. A study performed after we have started our study, indicate that the minimum
clinically important difference for GAF is 4 points [30]. Furthermore, the waiting-time from
Table 4. Subgroup analyses: IMR attendance, diagnosis and sex, end of intervention results.
0–10 sessions
(N = 42)
10+ sessions
(N = 57)
Attendance in IMR Mean SD† N Mean SD N P-value
GAF-F 43.8 15.6 20 46.7 10.8 52 0.49
PSP 47.6 18.6 20 55.2 9.9 51 0.11
PANSS 59.7 19.4 18 56.1 14.8 51 0.19
IMR TAU‡
Diagnosis Mean SD N Mean SD N P-value
Schizophrenia GAF-F§ 44.2 11.2 56 42.0 11.5 60 0.11
PSP|| 50.8 12.6 55 47.5 14.6 59 0.16
PANSS¶ 60.0 15.7 54 61.1 17.8 57 0.71
Bipolar disorder GAF-F 52.1 14.4 16 51.0 13.9 21 0.79
PSP 60.6 13.0 16 55.5 13.5 20 0.24
PANSS 46.5 12.8 15 49.8 12.7 19 0.57
Sex
Male GAF-F 45.0 11.0 42 41.6 11.6 46 0.10
PSP 55.0 15.0 41 53.0 15.0 45 0.06
PANSS 58.6 16.6 41 61.1 19.0 44 0.43
Female GAF-F 48.1 14.0 30 47.2 13.7 35 0.80
PSP 51.5 11.8 30 47.0 14.0 34 0.59
PANSS 55.0 15.1 28 54.3 13.3 32 0.81
Illness management and recovery
† Standard deviation
‡ Treatment as usual
§ Global Assessment of Functioning
|| Personal and Social Performance
¶ Positive and Negative Syndrome Scale
Analyses based on ANCOVA
https://doi.org/10.1371/journal.pone.0194027.t004
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randomization to the first IMR group session was on average 87 days and this can have affected
the results, since it is important to provide psychosocial treatment when a participant is interested
and motivated for it, and this may not be the case in the present study as there was a significant
delay from the time a participant said yes to the treatment until they started actually started. There-
fore we did a post-hoc analysis to see if the ones attending from 0–10 sessions waited longer than
the ones attending 10+ sessions had a longer waiting time, but this was not the case, indicating that
the waiting time didn’t affect the motivation for participating in the IMR program. Moreover, only
57.6% were fully exposed to the IMR program and this may have influenced the outcome measure.
Therefore we did a subgroup analyses to see if the degree of exposure to IMR affected the primary
and secondary outcomes. This was not the case. Finally, it is also a limitation that the secondary
outcome Personal and Social Performance scale was not validated in Danish. However, the scale
has been validated in a number of other countries and seems reliable and valid.
Overall IMR did not differ from treatment as usual in any of the analyzed outcomes. This
means that IMR added to treatment as usual in a Danish context does not result in better or
worse outcomes for the participants. A possible explanation is that the participants already
received a sufficient high quality treatment as part of the usual treatment and perhaps mental
health services and the intensity of it in Denmark is somewhat bigger compared to other coun-
tries, and that IMR in that context does not add anything further.
Another possible explanation can be found in the theoretic framework for IMR. According
to the theory of the IMR program clinical recovery outcomes such as functioning and symp-
toms remission are considered to be distal outcomes, therefore a longer follow-up period is
needed to address the effectiveness of the IMR program properly. Improvements in function-
ing is supposed to be found after the participant has adapted the new illness management skills
into his/hers life. Perhaps the reason why this trial did not find any difference between IMR
and the treatment as usual is that the period of follow-up was too brief. Without setting an
exact time frame for the IMR theory maybe this trial assessed a distal outcome in a proximal
short-time perspective (post treatment). A longer follow-up assessment could perhaps show if
IMR is effective according to global assessment of functioning and the other distal clinical
recovery outcomes. The trial is therefore also designed to have a longer follow-up and a
12-month after post treatment follow-up is completed currently.
Conclusion
IMR had no significant effect on the primary outcome GAF-F at the end of intervention (differ-
ence of 2.5 points in favor of IMR, P = 0.21). The 95% confidence interval (-1.4 point to +-
6.4points) makes the possibility of the hypothesized difference of 6 points favoring IMR unlikely.
IMR was not significantly different from treatment as usual at end of intervention in terms of
clinical outcomes such as level of functioning, symptoms severity, or service utilization.
This randomized trial contributes to the evidence base of IMR by providing a methodologi-
cal solid base for its conclusions; however the trial has some important limitations. More
research is needed to get a firm answer on the effectiveness of the IMR.
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